• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Future-proofing biobanks' governance.为生物银行的治理做好前瞻性规划。
Eur J Hum Genet. 2020 Aug;28(8):989-996. doi: 10.1038/s41431-020-0646-4. Epub 2020 May 18.
2
Transparency About Governance Contributes to Biobanks' Trustworthiness: Call for Action.透明度有助于生物库的信誉:行动呼吁。
Biopreserv Biobank. 2021 Feb;19(1):83-85. doi: 10.1089/bio.2020.0057. Epub 2020 Oct 30.
3
Accountability, governance and biobanks: the ethics and governance committee as guardian or as toothless tiger?责任、治理与生物库:伦理与治理委员会是守护者还是纸老虎?
Health Care Anal. 2011 Sep;19(3):231-46. doi: 10.1007/s10728-011-0195-7.
4
Taiwan Regulation of Biobanks.台湾生物样本库的管理规定
J Law Med Ethics. 2015 Winter;43(4):816-26. doi: 10.1111/jlme.12322.
5
Access Governance for Biobanks: The Case of the BioSHaRE-EU Cohorts.生物样本库的访问管理:以BioSHaRE-EU队列为例。
Biopreserv Biobank. 2016 Jun;14(3):201-6. doi: 10.1089/bio.2015.0124. Epub 2016 May 16.
6
Challenges in biobank governance in Sub-Saharan Africa.撒哈拉以南非洲生物银行治理面临的挑战。
BMC Med Ethics. 2013 Sep 11;14:35. doi: 10.1186/1472-6939-14-35.
7
The emergence of biobanks in the legal landscape: towards a new model of governance.生物样本库在法律环境中的出现:迈向一种新的治理模式。
J Law Soc. 2012;39(1):113-30. doi: 10.1111/j.1467-6478.2012.00573.x.
8
Transparency of Biobank Access in Canada: An Assessment of Industry Access and the Availability of Information on Access Policies and Resulting Research.加拿大生物样本库访问的透明度:对行业访问以及访问政策和相关研究信息可用性的评估
J Empir Res Hum Res Ethics. 2017 Dec;12(5):310-325. doi: 10.1177/1556264617723137. Epub 2017 Aug 17.
9
[Ethical, legal and social issues publications on biobanks 2011-2018. A scoping review.].[2011 - 2018年生物样本库的伦理、法律和社会问题出版物。一项范围综述。]
Rev Esp Salud Publica. 2020 Jun 25;94:e202006031.
10
[Ethical review of biobanks in The Netherlands: lessons from the String of Pearls Initiative].[荷兰生物样本库的伦理审查:来自“珍珠链计划”的经验教训]
Ned Tijdschr Geneeskd. 2011;155(26):A3557.

引用本文的文献

1
The research relationship: participant perspectives on consent in biobanking.研究关系:生物样本库中参与者对知情同意的看法。
BMC Med Ethics. 2025 Apr 12;26(1):47. doi: 10.1186/s12910-025-01199-0.
2
The Regulatory Landscape of Biobanks In Europe: From Accreditation to Intellectual Property.欧洲生物样本库的监管格局:从认证到知识产权
Curr Genomics. 2025;26(1):15-23. doi: 10.2174/0113892029313697240729091922. Epub 2024 Jul 30.
3
A β-Thalassemia Cell Biobank: Updates, Further Validation in Genetic and Therapeutic Research and Opportunities During (and After) the COVID-19 Pandemic.一个β地中海贫血细胞生物样本库:更新情况、在基因与治疗研究中的进一步验证以及新冠疫情期间(及之后)的机遇
J Clin Med. 2025 Jan 6;14(1):289. doi: 10.3390/jcm14010289.
4
Data Management in Biobanking: Strategies, Challenges, and Future Directions.生物样本库中的数据管理:策略、挑战与未来方向。
BioTech (Basel). 2024 Sep 2;13(3):34. doi: 10.3390/biotech13030034.
5
Supporting Stewardship: Funding, Utilization, and Sustainability as Ethical Concerns in Networked Biobanking.支持管理工作:联网生物样本库中作为伦理问题的资金、利用与可持续性
AJOB Empir Bioeth. 2025 Jan-Mar;16(1):42-51. doi: 10.1080/23294515.2024.2399533. Epub 2024 Sep 9.
6
Artificial Intelligence Needs Data: Challenges Accessing Italian Databases to Train AI.人工智能需要数据:访问意大利数据库以训练人工智能所面临的挑战
Asian Bioeth Rev. 2024 Jun 13;16(3):423-435. doi: 10.1007/s41649-024-00282-9. eCollection 2024 Jul.
7
Risk mapping for better governance in biobanking: the case of biobank.cy.生物样本库更好治理的风险映射:以biobank.cy为例
Front Genet. 2024 Jun 14;15:1397156. doi: 10.3389/fgene.2024.1397156. eCollection 2024.
8
Do biobanks need pharmacists? Support of pharmacy students to biobanking of human biological material for pharmaceutical research and development.生物样本库需要药剂师吗?药学专业学生对用于药物研发的人类生物样本生物样本库的支持。
Front Pharmacol. 2024 May 10;15:1406866. doi: 10.3389/fphar.2024.1406866. eCollection 2024.
9
Unlocking the potential of big data and AI in medicine: insights from biobanking.挖掘大数据与人工智能在医学中的潜力:生物样本库的见解
Front Med (Lausanne). 2024 Jan 31;11:1336588. doi: 10.3389/fmed.2024.1336588. eCollection 2024.
10
A leap of faith: building the trust in human biobanks.信念的飞跃:建立对人类生物样本库的信任。
Front Genet. 2023 Oct 19;14:1261623. doi: 10.3389/fgene.2023.1261623. eCollection 2023.

为生物银行的治理做好前瞻性规划。

Future-proofing biobanks' governance.

机构信息

ETH Zürich, Department of Health Sciences and Technology, Health Ethics and Policy Lab, Zürich, Switzerland.

出版信息

Eur J Hum Genet. 2020 Aug;28(8):989-996. doi: 10.1038/s41431-020-0646-4. Epub 2020 May 18.

DOI:10.1038/s41431-020-0646-4
PMID:32424324
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7468350/
Abstract

Good biobank governance implies-at a minimum-transparency and accountability and the implementation of oversight mechanisms. While the biobanking community is in general committed to such principles, little is known about precisely which governance strategies biobanks adopt to meet those objectives. We conducted an exploratory analysis of governance mechanisms adopted by research biobanks, including genetic biobanks, located in Europe and Canada. We reviewed information available on the websites of 69 biobanks, and directly contacted them for additional information. Our study identified six types of commonly adopted governance strategies: communication, compliance, expert advice, external review, internal procedures, and partnerships. Each strategy is implemented through different mechanisms including, independent ethics assessment, informed consent processes, quality management, data access control, legal compliance, standard operating procedures and external certification. Such mechanisms rely on a wide range of bodies, committees and actors from both within and outside the biobanks themselves. We found that most biobanks aim to be transparent about their governance mechanisms, but could do more to provide more complete and detailed information about them. In particular, the retrievable information, while showing efforts to ensure biobanks operate in a legitimate way, does not specify in sufficient detail how governance mechanisms support accountability, nor how they ensure oversight of research operations. This state of affairs can potentially undermine biobanks' trustworthiness to stakeholders and the public in a long-term perspective. Given the ever-increasing reliance of biomedical research on large biological repositories and their associated databases, we recommend that biobanks increase their efforts to future-proof their governance.

摘要

良好的生物样本库治理至少意味着透明度和问责制,以及实施监督机制。虽然生物样本库界普遍致力于这些原则,但对于生物样本库为实现这些目标而采用的具体治理策略知之甚少。我们对位于欧洲和加拿大的研究型生物样本库(包括遗传生物样本库)采用的治理机制进行了探索性分析。我们审查了 69 个生物样本库网站上提供的信息,并直接联系他们以获取更多信息。我们的研究确定了六种常见的治理策略类型:沟通、合规、专家建议、外部审查、内部程序和伙伴关系。每种策略都通过不同的机制来实施,包括独立的伦理评估、知情同意程序、质量管理、数据访问控制、法律合规性、标准操作程序和外部认证。这些机制依赖于生物样本库内外的广泛机构、委员会和参与者。我们发现,大多数生物样本库旨在对其治理机制保持透明,但可以做更多工作,提供更完整和详细的信息。特别是,虽然可检索信息显示了生物样本库确保自身合法运作的努力,但没有足够详细地说明治理机制如何支持问责制,也没有说明如何确保对研究活动进行监督。从长远来看,这种情况可能会破坏生物样本库对利益相关者和公众的可信度。鉴于生物医学研究对大型生物存储库及其相关数据库的依赖程度不断增加,我们建议生物样本库加大努力,为其治理提供未来保障。